At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
ITCA 650 (exenatide in DUROS)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating ITCA 650 (exenatide in DUROS) for Type 2 Diabetes. Completed, enrolled 44 participants across 3 sites.
Detailed Summary
evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
Primary CompletionMay 2009
First PostedFeb 2013
TodayJul 2026
First PostedFeb 25, 2013
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.4 years ago
Interventions
ITCA 650 (exenatide in DUROS)drug